NPM1 and acute leukemia: Furthermore, a phase I study sponsored by the City of Hope Medical Center is investigating the safety and tolerability of revumenib as a maintenance therapy in patients (>2 years old) with KMT2A-r or NPM1-m acute leukemia after HSCT (NCT06575296).